Insys Therapeutics Inc. (NASDAQ:INSY) dropped 3.1% during trading on Monday . The stock traded as low as $15.06 and last traded at $15.17, with a volume of 641,349 shares traded. The stock had previously closed at $15.66.

INSY has been the topic of several recent research reports. Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Insys Therapeutics in a research report on Tuesday, April 12th. Zacks Investment Research upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Wednesday, June 29th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $28.00 price objective on shares of Insys Therapeutics in a research report on Wednesday, July 6th. Jefferies Group decreased their price objective on shares of Insys Therapeutics from $23.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, April 12th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $32.00 price objective (down from $44.00) on shares of Insys Therapeutics in a research report on Tuesday, April 12th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $23.83.

The stock has a market cap of $1.09 billion and a P/E ratio of 21.94. The stock’s 50-day moving average price is $14.48 and its 200-day moving average price is $17.01.

Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings data on Thursday, April 28th. The specialty pharmaceutical company reported $0.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.04. The company earned $62 million during the quarter, compared to the consensus estimate of $61.31 million. The firm’s revenue was down 12.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.63 earnings per share. Equities research analysts predict that Insys Therapeutics Inc. will post $0.36 earnings per share for the current year.

In related news, Director Theodore H. Stanley sold 16,000 shares of the firm’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $16.27, for a total value of $260,320.00. Following the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $292,860. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder John N. Kapoor Trust Dated Sept acquired 50,000 shares of the business’s stock in a transaction that occurred on Thursday, May 12th. The stock was bought at an average cost of $12.84 per share, for a total transaction of $642,000.00. Following the completion of the purchase, the insider now directly owns 31,982 shares in the company, valued at approximately $410,648.88. The disclosure for this purchase can be found here.

Several hedge funds and institutional investors recently modified their holdings of INSY. GSA Capital Partners LLP increased its position in shares of Insys Therapeutics by 725.6% in the fourth quarter. GSA Capital Partners LLP now owns 226,712 shares of the specialty pharmaceutical company’s stock worth $6,491,000 after buying an additional 199,252 shares during the last quarter. Russell Frank Co increased its position in shares of Insys Therapeutics by 57.5% in the fourth quarter. Russell Frank Co now owns 275,455 shares of the specialty pharmaceutical company’s stock worth $8,093,000 after buying an additional 100,563 shares during the last quarter. California Public Employees Retirement System increased its position in shares of Insys Therapeutics by 178.7% in the fourth quarter. California Public Employees Retirement System now owns 97,000 shares of the specialty pharmaceutical company’s stock worth $2,777,000 after buying an additional 62,200 shares during the last quarter. Globeflex Capital L P increased its position in shares of Insys Therapeutics by 99,000.0% in the fourth quarter. Globeflex Capital L P now owns 39,640 shares of the specialty pharmaceutical company’s stock worth $1,135,000 after buying an additional 39,600 shares during the last quarter. Finally, Bank of Montreal Can increased its position in shares of Insys Therapeutics by 9.4% in the fourth quarter. Bank of Montreal Can now owns 66,646 shares of the specialty pharmaceutical company’s stock worth $1,909,000 after buying an additional 5,733 shares during the last quarter.

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys, a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV), and anorexia associated with weight loss in patients with AIDS.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.